Regenxbio Enterprise Value Over E B I T D A from 2010 to 2024

RGNX Stock  USD 9.59  0.41  4.47%   
Regenxbio Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA will likely drop to -3.68 in 2024. During the period from 2010 to 2024, Regenxbio Enterprise Value Over EBITDA regression line of annual values had significance of  0.0005 and arithmetic mean of (32.58). View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(3.51)
Current Value
(3.68)
Quarterly Volatility
42.48774186
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Regenxbio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenxbio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.2 M, Interest Expense of 6.5 M or Selling General Administrative of 47.8 M, as well as many indicators such as Price To Sales Ratio of 8.26, Dividend Yield of 0.0 or PTB Ratio of 2.64. Regenxbio financial statements analysis is a perfect complement when working with Regenxbio Valuation or Volatility modules.
  
Check out the analysis of Regenxbio Correlation against competitors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Latest Regenxbio's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Regenxbio over the last few years. It is Regenxbio's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regenxbio's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Regenxbio Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(32.58)
Coefficient Of Variation(130.42)
Mean Deviation37.61
Median(12.93)
Standard Deviation42.49
Sample Variance1,805
Range126
R-Value0.78
Mean Square Error746.81
R-Squared0.62
Significance0.0005
Slope7.46
Total Sum of Squares25,273

Regenxbio Enterprise Value Over E B I T D A History

2024 -3.68
2023 -3.51
2022 -4.0
2021 6.66
2020 -14.72
2019 -16.0
2018 15.92

About Regenxbio Financial Statements

Regenxbio investors use historical fundamental indicators, such as Regenxbio's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Regenxbio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(3.51)(3.68)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.